Production & Manufacturing
Process & Production

Amaran to construct a new plant and drug trial center

PBR Staff Writer Published 29 July 2013

Amaran Biotechnology, a Taipei-based drug manufacturer, has revealed plans to invest $33.41m in the construction of a factory and a research center at Hsinchu Biomedical Science Park.

The research center at the new facility, which is likely to start operations in the first quarter of 2014, will be used to carry out clinical trials and manufacture OBI Pharma-developed drugs, according to the company.

Production at the factory will focus on botulinum toxin type A biosimilar, along with other generic protein drugs.

The new facilities will be built under level 3 biosafety conditions and is claimed to be the country's first plant to be established in line with such conditions.

OBI Pharma chairman Michael Chang and Ruentex Group chairman Samuel Yin formed Amaran in 2010, as part of joint investment agreement.

An OBI Pharma official was quoted by Taipei Times as saying, "If our OBI-822/821 drug -- which is used to treat breast cancer -- can pass the third stage of clinical trials in Taiwan, the new factory will manufacture the drug for us."